Biggest News Aggregation in the World
📰 Further Support News

Page 3 - Further Support News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Further Support. Real-time updates on events, politics, business and more.

Seagen Inc.: Seagen Announces Long-Term Results from TUKYSA (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting

(0) - Updated Analysis Shows Median Overall Survival for TUKYSA Arm Extended to Two Years, with Benefit Maintained Across All Prespecified Patient Subgroups in HER2CLIMB Trial - - Results Further Support TUKYSA as Well-Tolerated Treatment Option That Improves Survival in Patients with Previously Treated Metastatic HER2-Positive Breast Cancer With and Without Brain Metastases - Seagen Inc. (Nasdaq:SGEN) today announced that improvements in overall survival (OS) and progression-free survival ...
United States David Caouette Rogerd Dansey Giuseppe Curigliano Peggy Pinkston American Society Of Clinical Oncology

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science